Home > Boards > US Listed > Biotechs >

Neptune tech and Bio-Resources (NEPT)

Add NEPT Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 10/16/2019 10:01:56 PM - Followers: 60 - Board type: Free - Posts Today: 5


I first heard about this stock when it was trading at the $2.32 mark a few weeks ago. Now we're hearing that more institutional buying and high profile firms are getting ready to take positions. That, in-turn, should lead to even more buying by retail investors. It's the stock snowball and visibility effect and this company deserves it 

About Neptune

Neptune Technologies & Bioressources Inc. researches, develops and commercializes proprietary bioactive ingredients and products with superior added-value and clinically proven health benefits. The Company extracts a range of bioactive ingredients such as novel proprietary omega-3 phospholipids from abundant yet underexploited marine biomass including Krill, a cold deep water zooplankton. Neptune's first commercially available product is Neptune Krill Oil (NKO®), which represents the only clinically proven and scientifically acknowledged marine omega-3 phospholipids with cardiovascular, cognitive and anti-inflammatory benefits for human applications and which exhibits unmet safety, purity and stability and consequently denoting a new level of excellence in omega-3 standards.

Neptune is pursuing market opportunities in the nutraceutical market including dietary supplements and functional foods. The Company is benefiting from opportunities in the pharmaceutical market through its pharmaceutical subsidiaries Acasti Pharma and NeuroBioPharm (including medical food, over-the-counter and prescription drug applications).

The Mission of Neptune is to:

  • Research, Develop and Commercialize Novel Marine Bioactive Ingredients
  • Pursue opportunities in the nutraceutical markets
    • Dietary Supplement
    • Functional Food
  • Exploit pharmaceutical applications
    • Subsidiary Acasti Pharma Inc: Cardiovascular diseases
    • Subsidiary NeuroBioPharm Inc.: Neurodegenerative diseases
  • Validate Superiority, Safety & Effectiveness
  • Protect Intellectual Property
  •   Enter Commercialization Alliances and Partnership Licenses

Promising results from A new cholesterol drug have helped call attention to Neptune, which is aiming for cholesterol/hyperlipidemia's ultimate prize, but unlike most companies dealing with clinical studies and regulatory approvals, Neptune is a revenue generating company whose products are already marketed and distributed in over 20 countries worldwide.

The Versant Partners' report, subtitled: "Krill oil franchise poised to outperform in multiple consumer and medical markets" features a few key points of note.

With NEPT's fiscal year end being February, Mr. Loe is calling for:

* F2012 revenues of $21.79 million and earnings $4.34 million ($0.09 EPS)
* F2013 revenues of $32.39 million and earnings of $8.81 million ($0.17 EPS)
* F2014 revenues of $45.37 million and earnings of $15.69 million ($0.30 EPS)
Loe cited management plans to meet forecasted demand by increasing current plant production from 130 thousand kilograms of krill oil per year to 430 thousand kilograms per year by 2015, a 300% production increase.
The report pinned its share price targets not only on the business Neptune has in hand, but also its future. By far, the biggest foundation Mr. Loe constructed on which to base his conclusions came from his meticulous research into the product itself - Neptune Krill Oil or NKO as it is branded on the market - and all its further refined products, such as Acasti's drug candidate called 'CaPre'.

Along the way, Loe also gives a significant nod to the functional food alliances Neptune developed with Yoplait - which is 50% owned by General Mills - and the food manufacturing behemoth, Nestle.

Mr. Loe wrote that both Yoplait and Nestle "should conclude development," of their research into Neptune Krill Oil by the end of the current year and that assuming all goes well, the sales of krill-oil infused food products by these giants would be a major revenue driver for Neptune in 2013/14  About Acasti

Acasti Pharma is developing safe and effective pharmaceutical and medical applications with an initial focus on cardiovascular disease by leveraging the intellectual property, clinical data and know how developed by Neptune Technologies. The Company is advancing a portfolio of bioactive ingredients of proprietary novel omega-3 phospholipids through the pharmaceutical development pathway which includes prescription medical foods (MF), over-the-counter products (OTC), and prescription drugs (Rx). Phospholipids are the major component of cell membranes and essential for all vital cell processes. They are one of the principle constituents of High Density Lipoprotein (good cholesterol) and play, as such, an important role in modulating cholesterol efflux.

Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) stabilized by potent antioxidants. Evidence has demonstrated the anti-inflammatory properties of EPA and DHA regulating important biological functions including degenerative, arthritic, circulatory, digestive, and brain diseases. Delivering omega-3s functionalized on phospholipids helps optimize the omega-3 fatty acid therapeutic benefits. Potent antioxidants contribute to proper physiological regulation preventing free radical cellular damage, a common pathway for cardiovascular disease and inflammation as well as neurodegenerative disease 


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NEPT News: Report of Foreign Issuer (6-k) 07:55 AM
NEPT News: Neptune Achieves a Milestone with Completion of Phase II Expansion 06:30 AM
NEPT News: Neptune Achieves a Milestone with Completion of Phase II Expansion 06:30 AM
NEPT News: Neptune franchit une étape importante avec l'achèvement de la phase d'expansion II 06:30 AM
NEPT News: Report of Foreign Issuer (6-k) 10/09/2019 12:57:52 PM
News News Alert: Report of Foreign Issuer (6-k) 10/16/2019 07:55:42 AM
#483   Neptune Wellness Solutions Inc (NASDAQ:NEPT) Stake Lifted by FUNMAN 10/16/19 10:01:56 PM
#482   Short % Increase / Decrease ... 21 % FUNMAN 10/16/19 09:40:09 AM
#481   Complete release and comments - Nice find GE! FUNMAN 10/16/19 08:54:07 AM
#480   Neptune completes Phase II expansion at Quebec facility. GE_Jim 10/16/19 08:12:06 AM
#479   NEPT is gonna have its day. There Up3Stacks 10/16/19 07:40:32 AM
#478   FYI May get more of a bump wed. GE_Jim 10/15/19 04:58:45 PM
#477   Neptune Wellness Solutions Inc. Presenting at the Benzinga FUNMAN 10/15/19 04:39:18 PM
#476   If Valens reports good numbers tonight, NEPT will FUNMAN 10/15/19 12:37:43 PM
#475   Well that's the kind of headlines we need. GE_Jim 10/15/19 12:24:12 PM
#474   Best positioned cannabis stocks. FUNMAN 10/15/19 11:18:30 AM
#473   Yes it is, along with IFF. Thanks GE_Jim 10/13/19 05:17:17 PM
#472   NICE Conclusion about extractors! Here's Why Oct. 17 FUNMAN 10/10/19 09:29:13 AM
#471   Neptune - Our team of experts will be FUNMAN 10/09/19 03:57:54 PM
#470   I agree with most of what you said. FUNMAN 10/09/19 03:53:54 PM
#469   I'm of the mind that I like the FUNMAN 10/07/19 08:53:08 PM
#468   Thank-you for that information however...... nowwhat2 10/07/19 07:09:28 PM
#467   Neptune Wellness Solutions has a Hand in CBD FUNMAN 10/07/19 06:02:08 PM
#466   How to Navigate the Wild-Wild West World of FUNMAN 10/05/19 09:23:33 PM
#465   I was right, NEPT changed their business to FUNMAN 10/05/19 09:43:06 AM
#464   This is great for NEPT, but they won't FUNMAN 10/04/19 09:54:26 PM
#463   Not if the company was focusing on something FUNMAN 10/04/19 01:48:09 PM
#462   Whaaaat ?....In '17 and '16 their revs were nowwhat2 10/04/19 01:45:36 PM
#461   In 17 and 18 their revenues were much FUNMAN 10/04/19 01:40:51 PM
#460   Just wondering.....why I've never heard of these guys.... nowwhat2 10/04/19 01:28:58 PM
#459   I think NEPT tops breakeven with about a FUNMAN 10/04/19 01:12:35 PM
#458   Mkt cap = $444.9 nowwhat2 10/04/19 12:12:10 PM
#457   NEPT has to play "revenue-catch-up". Assuming they can, FUNMAN 10/04/19 12:05:27 PM
#456   Tidy info there Funman - Do please keep nowwhat2 10/04/19 11:59:11 AM
#455   Pretty big news - Neptune Announces New Strate FUNMAN 10/04/19 10:57:20 AM
#454   Pretty big news - Neptune Announces New Strate FUNMAN 10/04/19 10:57:11 AM
#453   Pretty big news - Neptune Announces New Strate FUNMAN 10/04/19 10:56:40 AM
#452   Neptune announces strategic collaboration with IFF Laval, Québec, FUNMAN 10/02/19 09:31:21 AM
#451   Neptune - Don’t miss the presentations by Martin FUNMAN 10/01/19 07:47:17 PM
#450   Neptune Wellness Solutions has big upside, GMP says FUNMAN 09/29/19 02:06:26 PM
#449   Thanks for all of those good thoughts. FUNMAN 09/27/19 11:08:11 PM
#448   Extractors don’t have anything proprietary other than their DS CPA 09/27/19 07:00:46 PM
#447   Neptune Wellness Solutions FUNMAN 09/27/19 02:42:42 PM
#446   The biggest players in the cannabis industry are FUNMAN 09/26/19 01:19:38 PM
#445   Cannabis WINS ... The SAFE Banking Act of FUNMAN 09/25/19 05:48:46 PM
#444   I see it a bit differently. They have DS CPA 09/25/19 04:14:58 PM
#443   This was unexpected ... Volume(Light) ... 716,468 FUNMAN 09/25/19 04:06:24 PM
#442   If the US House and then the Senate FUNMAN 09/25/19 02:57:35 PM
#441   I would echo your sentiments in regards to DS CPA 09/25/19 02:09:42 PM
#440   Thanks "DS CPA" for the detailed DD. I FUNMAN 09/25/19 01:57:08 PM
#439   No disagreement here. I own a significant number DS CPA 09/25/19 01:28:00 PM
#438   Yesterday's NEPT news: Neptune Wellness Solutions - We FUNMAN 09/25/19 09:46:37 AM
#437   This stock is already beaten down so it DS CPA 09/25/19 09:15:28 AM
#436   While the sector is getting killed, NEPT is FUNMAN 09/24/19 01:23:02 PM
#435   Neptune Wellness Solutions - We are pleased to FUNMAN 09/24/19 01:21:17 PM
#434   Neptune Announces New U.S. Customer Relationships FUNMAN 09/24/19 01:21:10 PM